Open AccessALK positivity on pleuroscopic pleural biopsy in lung adenocarcinoma
Author(s) -
Preyas J Vaidya,
Arvind Kate,
Deval Mehta,
Boman N Dhabar,
Prashant N. Chhajed
Publication year - 2016
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.154053
Subject(s) - crizotinib , adenocarcinoma , medicine , anaplastic lymphoma kinase , lung cancer , lung , pathology , biopsy , adenocarcinoma of the lung , oncology , cancer research , cancer , malignant pleural effusion
Lung cancer is the leading cause of cancer deaths worldwide, and around 75% to 80% of lung cancers are detected in advanced stage. Multiple genetic mutations are identified and reported in adenocarcinoma of the lung. Various pulmonary samples can be tested for molecular mutations in lung cancer. However, feasibility of molecular profiling of pleuroscopic pleural biopsies in lung adenocarcinoma is not reported. We describe a case of advanced adenocarcinoma of lung with positive anaplastic lymphoma tyrosine kinase mutation on pleuroscopic pleural biopsy and improved with oral crizotinib. The current case highlights the feasibility of pleuroscopy.-guided pleural biopsies in molecular profiling of lung adenocarcinoma.